73. Schwarzer,J.etal.Glycananalysisincellculture-basedinfluenzavaccinepro
duction:influenceofhostcelllineandvirusstrainontheglycosylationpatterno
viralhemagglutinin.Vaccine27,4325–4336(2009).
74. Chung, C. Y. etal. Snap Shot: N-glycosylationprocessingpathwaysacrossking
doms.Cell171,258–258.e251(2017).
75. Wang,C.C.etal.Glycansoninfluenzahemagglutininaffectreceptorbindingan
immuneresponse. Proc. Natl Acad. Sci. USA106,18137–18142(2009).
76. Chen,J.R.etal.Vaccinationofmonoglycosylatedhemagglutinininducescross
strainprotectionagainstinfluenzavirusinfections. Proc. Natl Acad. Sci. USA111
2476–2481(2014).
77. Henry,C.etal.Monoclonalantibodyresponsesafterrecombinanthemagglutini
vaccineversussubunitinactivatedinfluenzavirusvaccine:acomparativestudy.J
Virol.https://doi.org/10.1128/JVI.01150-19(2019).
78. Nachbagauer,R.etal.Agedependenceandisotypespecificityofinfluenzaviru
hemagglutininstalk-reactiveantibodiesinhumans. m Bio 7, e 01996–01915(2016)
79. Reichert,T.etal.Doesglycosylationasamodifieroforiginalantigenicsinexplai
thecaseagedistributionandunusualtoxicityinpandemicnovel H1N1influenza
BMCInfect.Dis.10,5(2010).
80. Wang,K.etal.Expressionandpurificationofaninfluenzahemagglutinin–on
step closer to a recombinant protein-based influenza vaccine. Vaccine 24
2176–2185(2006).
81. Treanor,J.J.etal.Protectiveefficacyofatrivalentrecombinanthemagglutini
proteinvaccine (Flu Blok(R)) against influenzain healthyadults: a randomized
placebo-controlledtrial.Vaccine29,7733–7739(2011).
82. Belongia,E.A.etal.Clinicaltrialtoassessimmunogenicityofhigh-dose,adju
vanted, andrecombinantinfluenzavaccinesagainstcell-grown A(H3N2)viruse
inadults65to74years,2017-2018.Vaccine38,3121–3128(2020).
83. Shinde,V.etal.Inductionofcross-reactivehemagglutinationinhibitingantibod
and polyfunctional CD4+ T-cell responses by a recombinant matrix-M
adjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Dis
https://doi.org/10.1093/cid/ciaa1673(2020).
84. Centers for Disease Control Prevention. Estimates of deaths associated wit
seasonalinfluenza—United States,1976-2007. MMWRMorb. Mortal. Wkly Rep
59,1057–1062(2010).
85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, mer
thiolate,andultravioletlightuponinfluenzavirusinfectivitychickencellagglu
tination,hemagglutination,andantigenicity.Appl.Microbiol.19,290–294(1970)
86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of beta
propiolactone with nucleobase analogues, nucleosides, and peptides: implica
tionsfortheinactivationofviruses.J.Biol.Chem.286,36198–36214(2011).
87. She,Y.M.etal.Surfacemodificationsofinfluenzaproteinsuponvirusinactiva
tionbyβ-propiolactone.Proteomics13,3537–3547(2013).
88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect o
inactivationmethodsoninfluenzavirionstooptimize.Vaccin.Prod.Vaccin.37
1630–1637(2019).
89. Li,J.T.,Rank,M.A.,Squillace,D.L.&Kita,H.Ovalbumincontentofinfluenz
vaccines. J. Allergy Clin. Immunol.125,1412–1413(2010). authorreply 1413-1414
90. Garcia-Canas, V. et al. Selective and quantitative detection of influenza viru
proteinsincommercialvaccinesusingtwo-dimensionalhigh-performanceliqui
chromatographyandfluorescencedetection.Anal.Chem.79,3164–3172(2007)
91. Garcia-Canas,V.,Lorbetskie,B.&Girard,M.Rapidandselectivecharacterizationo
influenzavirusconstituentsinmonovalentandmultivalentpreparationsusin
non-porousreversed-phasehighperformanceliquidchromatographycolumns.J
Chromatogr.A1123,225–232(2006).